MedPath

High Intensity Functional Training in the Rehabilitation of Cancer Survivors

Not Applicable
Completed
Conditions
Cancer
Interventions
Other: High Intensity Functional Training
Registration Number
NCT04001127
Lead Sponsor
Andreas Lund Hessner
Brief Summary

The primary aim of this study is to investigate changes in health related quality of life (HRQoL) and cancer-related fatigue (CRF) following a 16-weeks of HIFT as a part of the rehabilitation of cancer survivors.

Additionally, we will investigate the continuation of participation in any High Intensity Functional Training (HIFT) program, three as well as 12 months following completion of the exercise intervention.

The intervention containing high intensity functional training will take place in a pragmatic clinical setting at the Center for Cancer and Health in Copenhagen.

We hypothesize that the HIFT will be be associated with improved HRQoL and CRF.

Detailed Description

Sample size Due to the exploratory nature of this study, no power calculation will be conducted. As the inclusion of participants will be consecutive, the anticipated number of included participants will be estimated based on the average monthly number of patients that begins the group based training during clinical practise at the centre. The average number of patients who is referred to the rehabilitation centre and who begins the HIFT training every month is 6 and thus, it is expected that a total of approximately 30 participants will be included in this study during a 22-week consecutive inclusion period that runs from august 5th 2019 to January 5th. All participants will be asked to complete both baseline-, end point- and three-month follow-up assessment.

Recruitment Due to the pragmatic design there will be no recruitment though advertisement. Recruitment will take place by asking eligible patients referred to CCHC, if they would like to participate in the study. This recruitment will take place during an initial rehabilitation planning session with a physiotherapist two days prior to the first HIFT session. Patients will be made aware that they have two days to consider participating in the study (informed consent material and written participant information can be found in appendix 3).

Methods: Data collection, management and analysis Data collection methods Plan for assessment and collection of outcomes All primary and secondary outcomes are participant-reported and will be administered through the online survey tool: SurveyXact. All included participants will receive an email with an electronic SurveyXact-invitation to the baseline questionnaire the same days as providing written consent to participate in the study. On the day of the final HIFT session (week 16), the participants will receive a similar SurveyXact-invitation with the end-point questionnaire. The three and 12-month follow up assessments will be administered in identical ways to the end-point assessment.

Patient characteristics Demographic variables will be included in the baseline questionnaire. These will include self-reported information about: sex, body mass index, educational level, employment, smoking status and physical activity level, and will be collected together with information on cancer type, time since cancer diagnosis, time since active treatment and cancer treatment type (See table 1 for data collection time points of patient characteristics and patient-reported outcome measures).

Registration of adverse events, plans to promote participant retention and complete follow up:

Adverse events and reasons for drop out from discontinued participant will be collected by practising physiotherapists at CCHC.

To minimize non-response and loss to follow-up participants will receive a reminder by email 4 and 14 days after receiving the email with end-point and follow-up questionnaire if they haven't provided their responses.

Data management All outcomes will be handled and stored electronically on a secure server for personal data, located at the University of Copenhagen.

No personal data will be exported from SurveyXact without pseudonymization. Complete anonymization of all data will be done after the last follow up period. Data protection agency approval Reference number: 514-0306/19-3000

Statistical methods Descriptive statistics will be used to summarize patient characteristics including age, sex, cancer diagnosis and type of treatment. Furthermore, leisure-time HIFT exercise and HRQoL at baseline will be summarized using the GSLTPAQ LSI score and the EORTC QLQ-C30 GH score respectively. Quantile Quantile plots and histograms will be used to evaluate distribution of standardized residuals. Continous data with normally distributed standardized residuals will be summarized using parametric statistics. Continous data with without normally distributed standardized residuals will be summarized as ordinal data, using non-parametric statistics. Categorical data will be summarized using frequencies and % of total.

The EORTC QLQ outcomes will be conducted according to the EORTC QLQ-C30 scoring manual (ref fayes 2001). Numerical data for each outcome with normal distributed standardized residuals, will be analysed from baseline to end-point with parametric statistics (paired t-test with equal variance). Single-Factor Repeated Measures Design will be conducted with a repeated measures one-way analysis of variance with four within subject time levels: baseline, end-point, three month follow up, and 12-month follow up. Summary statistics will include mean and confidence intervals for each outcome.

Numerical data for each outcome, without normal distributed standardized residuals, or ordinal data will be analyzed from baseline to end-point with non-parametric statistics (Wilcoxon signed-ranks test). Single-Factor Repeated Measures Design will be conducted with a Friedman two-way analysis of variance by ranks with four within subject time levels: baseline, end-point, three months follow up, and 12-month follow up. Summary statistics will include medians and interquartile ranges for each outcome, and visualizations will include bar charts with confidence intervals.

The association between leisure-time HIFT exercise and HRQoL will be analyzed on each time point with a linear regression model. To test whether the associations varies, the coefficients from the linear regression analyses will be compared.

Stata 15.1 (StataCorp, College Station, TX, USA) will be used for all statistical analyses and illustrations and an alpha level of 0.05 or less will be considered statistically significant.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
34
Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
High Intensity Functional TrainingHigh Intensity Functional TrainingIntervention group assigned to 16 weeks of group-based high intensity functional training supervised by physiotherapists.
Primary Outcome Measures
NameTimeMethod
Health related quality of lifeFor each participant at baseline + end point at 16 weeks + follow up at 3 month and 12 months)

Change in HRQoL from baseline to end point and from end point to follow up at 3 and 12 months, will be evaluated using the Global Health Status/Quality of Life item from the EORTC QLQ-C-30 questionnaire.

EORTC QLQ-C-30 includes five functional domains (physical, role, cognitive, emotional and social, where higher scores represent greater function or quality of life) and three symptom scales (fatigue, pain and nausea). Functional and symptom scales range from 0 to 100. Higher values on functional scales equal a higher level of functioning. Higher values on symptom scales equal higher symptom burden. EORTC QLQ-C-30 is chosen for it's established reliability and validity with specific emphasis on use in cancer populations

Secondary Outcome Measures
NameTimeMethod
Symptoms and functionFor each participant at baseline + end point at 16 weeks + follow up at 3 month and 12 months)

The secondary outcomes include functional scales (physical, role, emotional, cognitive, and social) and symptom scales (fatigue, nausea and vomiting, pain, dyspnea, insomnia, appetite loss, constipation, diarrhea, and financial difficulties) from the EORTC QLQ-C30 questionnaire (ref: Fayes 2001).

Leisure time physical activity levelTime frame for each participant: Baseline + end point at 16 weeks + follow up at 3 months and 12 months

Leisure time physical activity (LTPA) will be assessed using an original Danish translation of the Godin-Shephard Leisure-Time Physical Activity Questionnaire (GSLTPAQ) .The GSLTPAQ is frequently used in oncology research to assess LTPA.

The GSLTPAQ is a 4-item self-administered questionnaire. The first three questions ask for information on the number of times the respondant engages in mild, moderate and strenuous LTPA bouts of at least 15 min duration in a typical week. A score is then calculated for total leisure time based on the numerical values attributed to each of the three categories (9 for strenuous, 5 for moderate and 3 for light) multiplied by the frequency of the activity. The scores derived from this method is called a Leisure Score Index (LSI). In addition, scores obtained from moderate and strenuous physical activity can be used to classify respondents into active and insufficiently active categories.

Continued participation in high intensity functional training (post-intervention)Time frame: for each participant at follow up at 3 month and 12 months

Continued participation in any high intensity functional training (post-intervention HIFT) will be assessed using a single-item modified version of the (GSLTPAQ) asking participants: During a typical 7-Day period (a week), how many times on the average do you do High Intensity Functional Training (I.E. CrossFit) for more than 15 minutes during your free time. The participant responds by typing how many times per week, starting from zero.

Trial Locations

Locations (1)

Center for Cancer and Health Copenhagen

🇩🇰

Copenhagen, København N, Denmark

© Copyright 2025. All Rights Reserved by MedPath